Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO Royalty Sagard Healthcare Partners Acquires Rights to Agios 5% Royalty on TIBSOVO U.S. Net Sales CAMBRIDGE, Mass. and TORONTO

Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO Royalty

Sagard Healthcare Partners Acquires Rights to Agios 5%

Royalty on TIBSOVO U.S. Net Sales

CAMBRIDGE, Mass. and TORONTO,

October 27, 2022 Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, and Sagard Healthcare Partners

( Sagard ) today announced that Agios has sold its rights to 5% royalties on U.S. net sales of Servier s TIBSOVO (ivosidenib tablets) to Sagard for a one-time payment of $131.8 million. TIBSOVO is an oral, targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of

adult patients with an isocitrate dehydrogenase-1 (IDH1) mutation with acute myeloid leukemia (AML) or cholangiocarcinoma (bile duct cancer). In 2021, Agios completed the sale of its oncology portfolio

including TIBSOVO to Servier. Agios retains its rights to a potential future milestone payment of $200 million for vorasidenib, as well as 15% royalties on U.S. net sales

As a company solely focused on making an impact for people with rare and genetically defined diseases, this non-equity funding provides us with increased financial flexibility to continue to advance our mission, said Brian Goff, chief executive officer at Agios. As the result of a competitive process, we

achieved an attractive valuation for the TIBSOVO royalty and identified an agile and collaborative financial partner in Sagard Healthcare Partners. As we execute our PYRUKYND commercial launch, advance multiple pivotal studies across thalassemia, sickle cell disease and pediatric pyruvate kinase deficiency, and build a sustainable pipeline through both internally and

externally discovered assets, this deal enhances our ability to stay laser-focused on unlocking the greatest impact for people living with genetically defined diseases.

Agios is a pioneer in cellular metabolism with a track record of developing innovative, targeted therapies for patients with tremendous unmet

need, said David MacNaughtan, Partner & Head of Sagard Healthcare Partners. We are pleased to invest in TIBSOVO , which represents an important therapeutic approach for

patients with hematologic malignancies with an IDH1 mutation.

Wilmer Cutler Pickering Hale and Dorr LLP served as legal advisor to Agios. Mintz,

Levin, Cohn, Ferris, Glovsky & Popeo, PC acted as legal advisor to Sagard on the transaction.

Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals,

partners and colleagues to discover, develop and deliver therapies for rare and genetically defined diseases. In the U.S., Agios markets a first-in-class pyruvate kinase

(PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company s leadership in the field of cellular metabolism, Agios is advancing a robust

pipeline of investigational medicines with active and planned programs in alpha- and beta-thalassemia, sickle

cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research

team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company s website at www.agios.com.

Sagard is a multi-strategy alternative

asset manager with more than US$14 billion under management and professionals located in Canada, the U.S. and Europe. Sagard seeks attractive investment returns by combining its entrepreneurial and disciplined culture with flexible capital and

a unique global network of portfolio companies, limited partners, advisors and other valued relationships. As a firm, Sagard operates platforms that invest across five asset classes: venture capital, private equity, private credit, real estate

and healthcare royalties. Through its ecosystem partners, Sagard also engages in private wealth management and new venture creation.

Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation

Reform Act of 1995. Such forward-looking statements include those regarding Agios use of proceeds from the transaction with Sagard, Agios plans, strategies and expectations for the preclinical, clinical and commercial advancement of its

drug development programs, including PYRUKYND (mitapivat) and the potential benefits of Agios strategic plans and focus. The words anticipate, expect,

goal, hope, milestone, plan, potential, possible, strategy, will, vision, and similar expressions are intended to identify forward-looking

statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios

current expectations and beliefs. Management s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including,

without limitation risks and uncertainties related to: the impact of the COVID-19 pandemic on Agios business, operations, strategy, goals and anticipated milestones, including its ongoing and planned

research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of future approved products, and launching, marketing and selling future approved products;

Agios results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other

regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned

cash requirements and expenditures and competitive factors; Agios ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios ability to establish and

maintain collaborations; the failure of Agios to receive milestone or royalty payments related to the sale of its oncology business, the uncertainty of the timing of any receipt of any such payments, and the uncertainty of the results and

effectiveness of the use of proceeds from the transactions with Servier and Sagard; and general economic and market conditions. These and other risks are described in greater detail under the caption Risk Factors included in Agios

public filings with the Securities and

Exchange Commission. While the list of factors presented here is considered representative, this list should not be considered to be a complete statement of all potential risks and uncertainties.

Any forward-looking statements contained in this press release are made only as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect developments or information obtained after the date hereof and

disclaim any obligation to do so other than as may be required by law.

Senior Director, Investor Relations

Jessica Rennekamp, 857-209-3286

Senior Director, Corporate Communications